Evidence map›Paper›PMID 39535465›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials.

Rachel L Nosheny, Melanie Miller, Catherine Conti, Derek Flenniken, Miriam Ashford, Adam Diaz, Juliet Fockler, Diana Truran, Winnie Kwang, Shaveta Kanoria and 4 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rachel L NoshenyDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF), San Francisco, California, USA.
Melanie MillerNorthern California Institute for Research and Education, San Francisco, California, USA.
Catherine ContiNorthern California Institute for Research and Education, San Francisco, California, USA.
Derek FlennikenDepartment of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, California, USA.
Miriam AshfordNorthern California Institute for Research and Education, San Francisco, California, USA.
Adam DiazNorthern California Institute for Research and Education, San Francisco, California, USA.
Juliet FocklerDepartment of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, California, USA.
Diana TruranNorthern California Institute for Research and Education, San Francisco, California, USA.
Winnie KwangDepartment of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, California, USA.
Shaveta KanoriaNorthern California Institute for Research and Education, San Francisco, California, USA.
Dallas VeitchNorthern California Institute for Research and Education, San Francisco, California, USA.
Robert C GreenDivision of Genetics, Harvard University Medical Center, Boston, Massachusetts, USA.
Michael W WeinerDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF), San Francisco, California, USA.
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI ARTHUR W TOGA · 2016 to 2026
$226.7M
The Brain Health Registry for facilitating interdisciplinary aging researchR33AG062867 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NOSHENY, RACHEL LAUREN · 2020 to 2024
$3.2M
AbbVieAlzheimer's AssociationAlzheimer's Drug Discovery FoundationAraclon BiotechBioClinica, Inc.BiogenBristol-Myers Squibb CompanyCereSpir, Inc.CIHRCogstate; Eisai Inc.Elan Pharmaceuticals, Inc.Eli Lilly and CompanyEuroImmunFujirebioGE HealthcareIXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development, LLCJohnson & Johnson Pharmaceutical Research & Development LLCLumosity; LundbeckMerck & Co., Inc.Meso Scale Diagnostics, LLCNeuroRx ResearchNeurotrack TechnologiesNIANIA NIH HHS R33 AG062867NIA NIH HHS U19 AG024904NIBIB NIH HHSNIH/NIA U19AG024904Northern California Institute for Research and EducationNovartis Pharmaceuticals CorporationPfizer Inc.Piramal Imaging; ServierTakeda Pharmaceutical CompanyTransition Therapeutics
6 · The paper itself

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) Administrative Core oversees and coordinates all ADNI activities, to ensure the success and maximize the impact of ADNI in advancing Alzheimer's disease (AD) research and clinical trials. It manages finances and develops policies for data sharing, publications using ADNI data, and access to ADNI biospecimens. The Core develops and executes pilot projects to guide future ADNI activities and identifies key innovative methods for inclusion in ADNI. For ADNI4, the Administrative Core collaborates with the Engagement, Clinical, and Biomarker Cores to develop and evaluate novel, digital methods and infrastructure for participant recruitment, screening, and assessment of participants. The goal of these efforts is to enroll 500 participants, including > 50% from underrepresented populations, 40% with mild cognitive impairment, and 80% with elevated AD biomarkers. This new approach also provides a unique opportunity to validate novel methods. HIGHLIGHTS: The Alzheimer's Disease Neuroimaging Initiative (ADNI) Administrative Core oversees and coordinates all ADNI activities. The overall goal is to ensure ADNI's success and help design future Alzheimer's disease (AD) clinical trials. A key innovation is data sharing without embargo to maximize scientific impact. For ADNI4, novel, digital methods for recruitment and assessment were developed. New methods are designed to improve the participation of underrepresented populations.

Indexed as

Alzheimer DiseaseClinical Trials as TopicNeuroimagingBiomarkersCognitive DysfunctionHumansInformation DisseminationBiomarkersAlzheimer's diseaseAlzheimer's Disease Neuroimaging Initiativeclinical trialsdigital cognitive assessmentsunderrepresented populations

Identifiers

PMID39535465
PMCPMC11667550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.